JP6267649B2 - ポリマータンパク質微粒子 - Google Patents

ポリマータンパク質微粒子 Download PDF

Info

Publication number
JP6267649B2
JP6267649B2 JP2014542536A JP2014542536A JP6267649B2 JP 6267649 B2 JP6267649 B2 JP 6267649B2 JP 2014542536 A JP2014542536 A JP 2014542536A JP 2014542536 A JP2014542536 A JP 2014542536A JP 6267649 B2 JP6267649 B2 JP 6267649B2
Authority
JP
Japan
Prior art keywords
protein
polymer
poly
microparticles
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014542536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533698A5 (enExample
JP2014533698A (ja
Inventor
ハンター チェン
ハンター チェン
スコット ウォルシュ
スコット ウォルシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6267649(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2014533698A publication Critical patent/JP2014533698A/ja
Publication of JP2014533698A5 publication Critical patent/JP2014533698A5/ja
Application granted granted Critical
Publication of JP6267649B2 publication Critical patent/JP6267649B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2014542536A 2011-11-18 2012-11-18 ポリマータンパク質微粒子 Active JP6267649B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161561525P 2011-11-18 2011-11-18
US61/561,525 2011-11-18
PCT/US2012/065735 WO2013075068A1 (en) 2011-11-18 2012-11-18 Polymer protein microparticles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017149732A Division JP6549653B2 (ja) 2011-11-18 2017-08-02 ポリマータンパク質微粒子

Publications (3)

Publication Number Publication Date
JP2014533698A JP2014533698A (ja) 2014-12-15
JP2014533698A5 JP2014533698A5 (enExample) 2016-01-07
JP6267649B2 true JP6267649B2 (ja) 2018-01-24

Family

ID=47295198

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014542536A Active JP6267649B2 (ja) 2011-11-18 2012-11-18 ポリマータンパク質微粒子
JP2017149732A Active JP6549653B2 (ja) 2011-11-18 2017-08-02 ポリマータンパク質微粒子
JP2019079952A Active JP6727372B2 (ja) 2011-11-18 2019-04-19 ポリマータンパク質微粒子
JP2020112359A Active JP7217247B2 (ja) 2011-11-18 2020-06-30 ポリマータンパク質微粒子
JP2023007775A Active JP7542090B2 (ja) 2011-11-18 2023-01-23 ポリマータンパク質微粒子

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017149732A Active JP6549653B2 (ja) 2011-11-18 2017-08-02 ポリマータンパク質微粒子
JP2019079952A Active JP6727372B2 (ja) 2011-11-18 2019-04-19 ポリマータンパク質微粒子
JP2020112359A Active JP7217247B2 (ja) 2011-11-18 2020-06-30 ポリマータンパク質微粒子
JP2023007775A Active JP7542090B2 (ja) 2011-11-18 2023-01-23 ポリマータンパク質微粒子

Country Status (20)

Country Link
US (4) US20130129830A1 (enExample)
EP (4) EP2790681B9 (enExample)
JP (5) JP6267649B2 (enExample)
KR (4) KR102218223B1 (enExample)
CN (2) CN105688188A (enExample)
AU (1) AU2012340107B2 (enExample)
BR (1) BR112014011915B1 (enExample)
CA (2) CA2855749C (enExample)
DK (3) DK3384903T3 (enExample)
ES (4) ES2775104T5 (enExample)
FI (1) FI2790681T4 (enExample)
HU (2) HUE048597T2 (enExample)
IL (4) IL303832A (enExample)
MX (2) MX362286B (enExample)
PL (3) PL3574897T3 (enExample)
PT (2) PT3384903T (enExample)
RU (2) RU2642664C2 (enExample)
SG (2) SG11201402152YA (enExample)
WO (1) WO2013075068A1 (enExample)
ZA (4) ZA201403379B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3682905T3 (pl) 2011-10-03 2022-04-04 Modernatx, Inc. Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2017106716A1 (en) * 2015-12-16 2017-06-22 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
DK3394093T3 (da) 2015-12-23 2022-04-19 Modernatx Inc Fremgangsmåder til anvendelse af ox40-ligand-kodende polynukleotider
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
WO2017120612A1 (en) 2016-01-10 2017-07-13 Modernatx, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
EP3709971A2 (en) 2017-11-17 2020-09-23 Amgen Inc. Vegfr-fc fusion protein formulations
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
JP2022523063A (ja) * 2019-01-30 2022-04-21 アムジエン・インコーポレーテツド アフリベルセプトの属性、並びにその特性決定及び修飾方法
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021108548A1 (en) * 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
US12239687B2 (en) * 2020-11-25 2025-03-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
CN115887760A (zh) * 2022-11-21 2023-04-04 娜罗曼苏(杭州)医疗生物科技有限公司 一种注射用左旋聚乳酸制备工艺

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210529A (en) 1974-12-26 1980-07-01 Midwest Research Institute Blood compatible polymers and applications thereof
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US5104221A (en) 1989-03-03 1992-04-14 Coulter Electronics Of New England, Inc. Particle size analysis utilizing polarization intensity differential scattering
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
WO1994006452A1 (en) 1992-09-21 1994-03-31 The Upjohn Company Sustained-release protein formulations
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
DE69534701T2 (de) 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0913177A1 (de) 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
IL137388A (en) 1998-01-29 2005-05-17 Poly Med Inc Absorbable microparticles
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6223455B1 (en) * 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
WO2001030320A1 (en) 1999-10-22 2001-05-03 Amgen Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
FR2809309B1 (fr) * 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
AU2001281113B2 (en) 2000-08-07 2006-07-20 Nektar Therapeutics Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
NZ530700A (en) 2001-06-21 2009-02-28 Altus Pharmaceuticals Inc Spherical protein particles and methods of making and using them
CN1310671C (zh) * 2001-07-09 2007-04-18 安斯泰来制药有限公司 缓释注射剂用组合物的制造方法
TW574597B (en) 2002-03-08 2004-02-01 Asml Netherlands Bv Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
KR20050090430A (ko) 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
US20040208928A1 (en) * 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
WO2005000268A2 (en) 2003-06-26 2005-01-06 Control Delivery Systems, Inc. Bioerodible sustained release drug delivery systems
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
BRPI0414982A (pt) * 2003-10-01 2006-11-21 Debio Rech Pharma Sa dispositivo e método para produção de partìculas
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7727962B2 (en) 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
BRPI0514411B8 (pt) 2004-08-17 2021-05-25 Regeneron Pharma formulação, e, método de produzir uma formulação
US7572893B2 (en) 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US20060110429A1 (en) 2004-11-24 2006-05-25 Therakine Corporation Implant for intraocular drug delivery
KR100770362B1 (ko) 2004-12-30 2007-10-26 (주)두비엘 분무건조 고분자형 콜렉틴족 단백질 및 그의 제조방법
SI1861116T1 (sl) 2005-03-25 2015-12-31 Regeneron Pharmaceuticals, Inc. Formulacije antagonistov VEGF
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US8877229B2 (en) † 2005-12-02 2014-11-04 Eyetech Inc. Controlled release microparticles
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
SI2364691T1 (sl) 2006-06-16 2013-08-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
DE102006030164A1 (de) 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
DE102006030166A1 (de) 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
EP1958622A1 (en) 2006-11-07 2008-08-20 Royal College of Surgeons in Ireland Method of producing microcapsules
WO2008109886A1 (en) 2007-03-08 2008-09-12 The Regents Of The University Of California Topographically engineered structures and methods for using the same in regenerative medicine applications
EP2164425B1 (en) 2007-03-16 2015-10-28 The Regents of The University of California Nanostructure surface coated medical implants and methods of using the same
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド 質量を削減した長時間作用剤形
CN101903014B (zh) 2007-12-21 2014-04-16 默克专利股份有限公司 固体内核中包含生长激素的固体脂质微囊
CA2711984A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co. Kg Powdered protein compositions and methods of making same
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
SG173167A1 (en) 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
WO2010111132A2 (en) * 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
CN101559041B (zh) 2009-05-19 2014-01-15 中国科学院过程工程研究所 粒径均一的多肽药物缓释微球或微囊制剂及制备方法
MY152963A (en) 2009-06-26 2014-12-15 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
US8417452B2 (en) 2009-08-19 2013-04-09 General Motors Llc System for providing information to an operator of a vehicle
KR20120095371A (ko) * 2009-10-01 2012-08-28 에보닉 데구사 코포레이션 노화 황반변성 치료용 극미립자 조성물들 및 노화 황반변성 치료방법
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
SG187730A1 (en) 2010-08-05 2013-03-28 Forsight Vision 4 Inc Injector apparatus and method for drug delivery
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
MY158130A (en) 2010-10-06 2016-08-30 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies
SG10201602829PA (en) 2011-04-14 2016-05-30 Univ California Multilayer Thin Film Drug Delivery Device And Methods Of Making And Using The Same
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE048597T2 (hu) 2011-11-18 2020-07-28 Regeneron Pharma Módszer polimerbevonatú fehérje-mikrorészecskéket tartalmazó, elnyújtott hatóanyag-kibocsátású gyógyszerészeti készítmény gyártására porlasztva szárítással
EP2849723B1 (en) 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
JP6336442B2 (ja) 2012-05-30 2018-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物活性剤送達デバイス及びその製造方法と使用方法
WO2014039964A2 (en) 2012-09-10 2014-03-13 The Regents Of The University Of California Compounds and methods for modulating vascular injury
CN105120898A (zh) 2013-03-19 2015-12-02 生物技术工具公司 过敏原制剂
MX382864B (es) 2014-07-14 2025-03-13 Amgen Inc Formulaciones de anticuerpos cristalinos.
AU2016340072B2 (en) 2015-10-16 2021-10-28 Regeneron Pharmaceuticals, Inc. Stable protein compositions
AU2016349662A1 (en) 2015-11-05 2018-05-17 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US20200289514A1 (en) 2015-11-13 2020-09-17 Novartis Ag Novel Pyrazolo Pyrimidine Derivatives
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
EP3387062A2 (en) 2015-12-07 2018-10-17 Acetate International LLC Cellulose acetate film forming compositions
EP3390357B1 (en) 2015-12-15 2021-11-10 Merck Sharp & Dohme Corp. Biaryl monobactam compounds for the treatment of bacterial infections
WO2017106716A1 (en) 2015-12-16 2017-06-22 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US11951216B2 (en) 2011-11-18 2024-04-09 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Also Published As

Publication number Publication date
JP2019135255A (ja) 2019-08-15
BR112014011915A2 (pt) 2017-05-16
JP2020169195A (ja) 2020-10-15
IL277958B2 (en) 2023-11-01
BR112014011915B1 (pt) 2022-08-30
EP4026543A1 (en) 2022-07-13
ES2775104T5 (es) 2023-06-08
US20130129830A1 (en) 2013-05-23
JP7217247B2 (ja) 2023-02-02
RU2768492C2 (ru) 2022-03-24
ZA202000742B (en) 2024-06-26
HUE051644T2 (hu) 2021-03-01
PL2790681T5 (pl) 2024-02-05
PL3574897T3 (pl) 2022-05-09
CA2855749A1 (en) 2013-05-23
US20240207194A1 (en) 2024-06-27
US11291636B2 (en) 2022-04-05
ZA201800078B (en) 2020-05-27
JP2014533698A (ja) 2014-12-15
PT3574897T (pt) 2022-04-06
PT3384903T (pt) 2020-06-25
DK2790681T4 (da) 2023-05-01
IL303832A (en) 2023-08-01
IL232328A0 (en) 2014-06-30
EP3384903B1 (en) 2020-05-27
SG11201402152YA (en) 2014-06-27
PL3384903T3 (pl) 2020-10-19
EP2790681B1 (en) 2020-01-22
KR102218223B1 (ko) 2021-02-22
JP2023052564A (ja) 2023-04-11
EP2790681B9 (en) 2023-07-26
RU2018101248A (ru) 2019-02-21
ES2810003T3 (es) 2021-03-08
HUE048597T2 (hu) 2020-07-28
KR20140096327A (ko) 2014-08-05
PL2790681T3 (pl) 2020-07-27
US11951216B2 (en) 2024-04-09
US20220249387A1 (en) 2022-08-11
EP3574897B1 (en) 2022-01-05
WO2013075068A1 (en) 2013-05-23
JP2018008990A (ja) 2018-01-18
IL277958B1 (en) 2023-07-01
ES2775104T3 (es) 2020-07-23
MX2019000382A (es) 2023-01-05
ES2909777T3 (es) 2022-05-10
CA3076725A1 (en) 2013-05-23
CA2855749C (en) 2020-05-26
EP3384903A1 (en) 2018-10-10
IL232328B (en) 2018-11-29
RU2018101248A3 (enExample) 2021-02-18
DK3574897T3 (da) 2022-04-04
CN103957898A (zh) 2014-07-30
SG10202103003RA (en) 2021-05-28
DK2790681T3 (da) 2020-04-14
ES2985784T3 (es) 2024-11-07
JP6549653B2 (ja) 2019-07-24
DK3384903T3 (da) 2020-07-20
MX362286B (es) 2019-01-10
EP4026543B1 (en) 2024-08-07
JP7542090B2 (ja) 2024-08-29
ZA201403379B (en) 2020-12-23
IL262651B (en) 2020-11-30
RU2014124682A (ru) 2015-12-27
IL262651A (en) 2018-12-31
AU2012340107A1 (en) 2014-06-05
EP2790681B2 (en) 2023-02-22
AU2012340107B2 (en) 2017-06-15
KR102133352B1 (ko) 2020-07-14
ZA202400983B (en) 2025-05-28
CN103957898B (zh) 2016-02-24
EP2790681A1 (en) 2014-10-22
FI2790681T4 (fi) 2023-05-04
KR20220063293A (ko) 2022-05-17
RU2642664C2 (ru) 2018-01-25
US20170181978A1 (en) 2017-06-29
KR20200018712A (ko) 2020-02-19
IL277958A (en) 2020-11-30
CN105688188A (zh) 2016-06-22
MX2014005997A (es) 2014-08-27
JP6727372B2 (ja) 2020-07-22
KR20210021112A (ko) 2021-02-24
EP3574897A1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
JP7542090B2 (ja) ポリマータンパク質微粒子
HK40068076A (en) Polymer coated protein microparticles for extended release formulations for use in the vitreous of the eye for treating vascular eye disorders
HK40009968A (en) Polymer protein microparticles
HK40011471A (en) Extended release formulation comprising polymer protein microparticles for use in the vitreous of the eye for treating vascular eye disorders
HK40011471B (en) Extended release formulation comprising polymer protein microparticles for use in the vitreous of the eye for treating vascular eye disorders
HK1197374B (en) Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying
HK1197374A (en) Method of manufacturing an extended release pharmaceutical formulation comprising polymer coated protein microparticles using spray-drying

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170908

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171204

R150 Certificate of patent or registration of utility model

Ref document number: 6267649

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250